Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the…

By D. Nathan. Diabetes Care, 2009

1,818 citations recorded by the source corpus.

We appreciate Dr. Woo's response to our study (1) and his comparison (2) of the Canadian Diabetes Association (CDA) clinical practice guidelines and the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) consensus algorithm and welcome the opportunity to address the differences he has identified. The original ADA/EASD consensus algorithm and the subsequent revisions were developed independently by the consensus group and were then presented to the two major diabetes organizations for their review and approval of the process. Dr. Woo notes the CDA's process of data review with a “standardized evidence-based approach” and the participation of “over 90 authors and a steering committee of 18” and concludes that the process removed “as much bias as possible,” implying that this approach was superior to our consensus algorithm process. He further notes …

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/9420e54724ef1ad1604789328e7ba537b59a3632

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Citations in the corpus

Pharmacological management of obesity: an endocrine Society clinical practice guideline. (2015, background): “Evidence Insulin remains the most effective agent to control serum glucose (81).”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “Although the pharmacological options are each time more extensive and they offer more therapeutics possibilities, especially in the T2DM, the interventions in the life style are essentials in the approach of these patients and they are needed to get the therapeutics goals [13] .”
Standards of Medical Care in Diabetes—2009 (2009, background): “The ADA and the European Association for the Study of Diabetes published a consensus statement on the approach to management of hyperglycemia in individuals with type 2 diabetes (66) and recently published an update (67).”
AMPK: an emerging drug target for diabetes and the metabolic syndrome. (2009, background): “However, in addition to inadequate efficacy and durability, some of these agents suffer from liabilities, including hypoglycemia, weight gain, edema, fractures, lactic acidosis, and gastrointestinal intolerance (Nathan et al., 2009).”
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (2009, background): “See text for a detailed discussion (309).”
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis (2014, neutral): “Metformin is widely used to treat patients with type II diabetes mellitus who have high levels of circulating insulin (Nathan et al., 2009).”
The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. (2012, background): “Careful glycemic control is currently considered the cornerstone of diabetes management, and research has shown that reaching and maintaining treatment goals can result in a decreased risk of diabetes-related complications, lower costs, and less healthcare utilization (174,178).”
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug (2017, methodology): “coli were inoculated anaerobically in a Coy chamber (5% hydrogen, 10% carbon dioxide, and 85% nitrogen) as single colonies in 7 ml of brain-heart infusion (BHI) medium containing (in g/liter) yeast extract (5), cellobiose (1), maltose (1), cysteine (0.”